1. CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES. (12th June 2019) Authors: de Philippis, C.; Legrande, F.; Bramanti, S.; Montes de Oca, C.; Dulery, R.; Bouabdallah, R.; Granada, A.; Devillier, R.; Mariotti, J.; Sarina, B.; Harbi, S.; Maisano, V.; Furst, S.; Pagliardini, T.; Weiller, P.J.; Lemarie, C.; Calmels, B.; Chabannon, C.; Carlo‐Stella, C.; Santoro, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 298 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IMPACT OF CLASS II HLA MISMATCH ON CLINICAL OUTCOMES IN HODGKIN LYMPHOMA PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO‐SCT) WITH POST‐TRANSPLANT CYCLOPHOSPHAMIDE (PT‐CY). (12th June 2019) Authors: Castagna, L.; Bramanti, S.; Devillier, R.; Pagliardini, T.; Sarina, B.; Lemarie, C.; Furst, S.; Mariotti, J.; Granata, A.; de Philippis, C.; Harbi, S.; Legrand, F.; Maisano, V.; Bouabdallah, R.; Carlo‐Stella, C.; Calmels, B.; Chabannon, C.; Blaise, D.; Santoro, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 300 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗